Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1512203
This article is part of the Research Topic Innovative Therapeutic Approaches for Complex Cancers: Exploring New Strategies in Glioblastoma, Urogenital, and Bladder Cancers View all articles

Prognostic Model Based on Disulfidptosis-Related lncRNAs for Predicting Survival and Therapeutic Response in Bladder Cancer

Provisionally accepted
LIrui Han LIrui Han 1*Hankai Yang Hankai Yang 1*Xuan Jiang Xuan Jiang 1Ziyu Zhou Ziyu Zhou 1*Chang Ge Chang Ge 1*Kairan Yu Kairan Yu 1*Guofang Li Guofang Li 1*Yubo Liu Yubo Liu 1*Wei Wang Wei Wang 2*
  • 1 Dalian University of Technology, Dalian, China
  • 2 Department of Thoracic Surgery, Dalian University of Technology, Dalian, China

The final, formatted version of the article will be published soon.

    Background: With poor treatment outcomes and prognosis, bladder cancer remains a focus for clinical research in the precision oncology era. However, the potential of disulfidptosis, a novel cell death mechanism, and its related long non-coding RNAs to support selective cancer cell killing in this disease is still unclear.: We identified key disulfidptosis-related lncRNAs in bladder cancer, constructed a prognostic risk model with potential therapeutic targets, and confirmed the findings through quantitative PCR analysis. Results: We identified five crucial lncRNAs (AC005840.4, AC010331.1，AL021707.6, MIR4435-2HG and ARHGAP5-AS1) and integrated them into a predictive model centered on disulfidptosisassociated lncRNAs. Reliability and validity tests demonstrated that the lncRNA prediction index associated with disulfidptosis effectively discerns patients' prognosis outcomes. Additionally, highrisk patients exhibited elevated expression levels of genes involved in the PI3K-Akt signaling pathway, extracellular matrix organization, and immune escape mechanisms, which are associated with poor prognosis. Notably, high-risk patients demonstrated higher sensitivity to Sorafenib, Oxaliplatin and MK-2206, underscoring the promise of these lncRNAs as precise therapeutic targets in bladder cancer. Conclusion: By revealing the predictive importance of disulfidptosis-associated lncRNAs in bladder cancer, our research offers new perspectives and pinpoints potential therapeutic targets in clinical environments.

    Keywords: disulfidptosis, Bladder cancer, long non-coding RNA, machine learning, prognosis

    Received: 16 Oct 2024; Accepted: 12 Nov 2024.

    Copyright: © 2024 Han, Yang, Jiang, Zhou, Ge, Yu, Li, Liu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    LIrui Han, Dalian University of Technology, Dalian, China
    Hankai Yang, Dalian University of Technology, Dalian, China
    Ziyu Zhou, Dalian University of Technology, Dalian, China
    Chang Ge, Dalian University of Technology, Dalian, China
    Kairan Yu, Dalian University of Technology, Dalian, China
    Guofang Li, Dalian University of Technology, Dalian, China
    Yubo Liu, Dalian University of Technology, Dalian, China
    Wei Wang, Department of Thoracic Surgery, Dalian University of Technology, Dalian, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.